Evidence map›Paper›PMID 35450050›Full record

ArticleFrontiers in pharmacology2022

Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial.

Abu Taiub Mohammed Mohiuddin Chowdhury, Aktar Kamal, Kafil Uddin Abbas, Shubhashis Talukder, Md Rezaul Karim, Md Ahsan Ali, Md Nuruzzaman, Yarui Li, Shuixiang He

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. How to Restore Oxidative Balance That Was Disrupted by SARS-CoV-2 Infection.International journal of molecular sciences · 2022
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Abu Taiub Mohammed Mohiuddin ChowdhuryDepartment of Gastroenterology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Aktar KamalDepartment of Critical Care, M Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh.
Kafil Uddin AbbasDepartment of Critical Care, Cox's Bazar 250 Bed District Sadar Hospital, Cox's Bazar, Bangladesh.
Shubhashis TalukderDepartment of Critical Care, 250 Bed Chattogram General Hospital, Chattogram, Bangladesh.
Md Rezaul KarimHubei Key Laboratory of Embryonic Stem Cell Research, Institute of Neuroscience, Hubei University of Medicine, Shiyan, China.
Md Ahsan AliDepartment of Histology, Xi'an Jiaotong University, Xi'an, China.
Md NuruzzamanDepartment of Internal Medicine, M Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh.
Yarui LiDepartment of Gastroenterology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Shuixiang HeDepartment of Gastroenterology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Dinajpur Medical College · BDFirst Affiliated Hospital of Xi'an Jiaotong University · CNHubei University of Medicine · CNMinistry of Health and Family Welfare · BDXi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BangladeshCOVID-19COVID-19 ARDSdexamethasoneremdecivirSARS-Cov-2tocilizumab

Identifiers

PMID35450050
PMCPMC9017992
OpenAlexW4226000022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.